Clinical Trial Update: A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for doravirine/islatravir (MK-8591A) in HIV-1 infection, focusing on participants who previously received the regimen; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• DOR/ISL (doravirine/islatravir) (doravirine/islatravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING